
FIG. 1A
4T1-moB7H4/H3 Tumor Growth
Tumor Volume (Mean mm3 ± SD)
Days post inoculation
mIgG
20502-mIgG2a-F
Anti-PD-1
Combo
FIG. 1B
Day 33 Tumor volumes
Tumor volume mm3
mIgG
20502-mIgG2a-F
anti-PD-1
Combo
****
*
FIG. 1C
Percent Survival
Time (days)
mIgG
20502-mIgG2a-F (20mg/kg)
anti-PD-1 (5mg/kg)
20502-mIgG2a-F+anti-PD-1


Tumor Volume (mm³)
1600
1400
1200
1000
800
600
400
200
0
*
mIgG
30
20
10
3
1
0.3
20502-mIgG2a-F
Day 30; * = P < 0.05

FIG. 2


B16-moB7-H4/H3 Model
Percent survival
days post tumor implant
① Combo – 3 mg/kg
② Combo – 0.3 mg/kg
③ Combo – 30 mg/kg
④ 30 mg/kg
⑤ anti-PD-1
⑥ 3 mg/kg
⑦ 0.3 mg/kg
⑧ mslgG2a
4T1-moB7-H4/H3 Model
Percent survival
days post tumor implant
① Combo – 30 mg/kg
② Combo – 3 mg/kg
③ Combo – 0.3 mg/kg
④ anti-PD-1
⑤ 0.3 mg/kg
⑥ 30 mg/kg
⑦ 3 mg/kg
⑧ mslgG2a

FIG. 3